1019results about "Spray delivery" patented technology

The present invention relates to a process for producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentrine particles, wherein the process comprises: (a) heating ensifentrine particles at a temperature of from 100° C. to 220° C. to obtain sterile ensifentrine particles; and (b) combining the sterile ensifentrine particles with a sterile liquid vehicle to produce the sterile liquid pharmaceutical composition suitable for administration by inhalation. A process for producing an ampule comprising the sterile liquid pharmaceutical composition is also described.

The disclosure relates to a particulate composition comprising ensifentrine, wherein the particulate composition further comprises: from greater than 0.00 wt % to 0.60 wt % of 1,3-bis(2-(2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido [6,1-a]isoquinolin-3(4H)-yl)ethyl)urea (BMIQU) relative to the total weight of ensifentrine; and from 0.00 wt % to 0.50 wt % of a biuret impurity of formula (A) relative to the total weight of ensifentrine. Further disclosed herein are liquid pharmaceutical compositions comprising the particulate composition, and a process for producing the particulate composition are also described.

The disclosure relates to a particulate composition comprising ensifentrine, wherein the particulate composition further comprises: from greater than 0.00 wt % to 0.60 wt % of 1,3-bis(2-(2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl)ethyl)urea (BMIQU) relative to the total weight of ensifentrine; and from 0.00 wt % to 0.50 wt % of a biuret impurity of formula (A) relative to the total weight of ensifentrine. Further disclosed herein are liquid pharmaceutical compositions comprising the particulate composition, and a process for producing the particulate composition are also described.

The disclosure relates to a particulate composition comprising ensifentrine, wherein the particulate composition further comprises: from greater than 0.00 wt % to 0.60 wt % of 1,3-bis(2-(2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl)ethyl)urea (BMIQU) relative to the total weight of ensifentrine; and from 0.00 wt % to 0.50 wt % of a biuret impurity of formula (A) relative to the total weight of ensifentrine. Further disclosed herein are liquid pharmaceutical compositions comprising the particulate composition, and a process for producing the particulate composition are also described.

The present invention relates to a process for producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentrine particles, wherein the process comprises: (a) heating ensifentrine particles at a temperature of from 100° C. to 220° C. to obtain sterile ensifentrine particles; and (b) combining the sterile ensifentrine particles with a sterile liquid vehicle to produce the sterile liquid pharmaceutical composition suitable for administration by inhalation. A process for producing an ampule comprising the sterile liquid pharmaceutical composition is also described.

The disclosure relates to a particulate composition comprising ensifentrine, wherein the particulate composition further comprises: from greater than 0.00 wt % to 0.60 wt % of 1,3-bis(2-(2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl)ethyl)urea (BMIQU) relative to the total weight of ensifentrine; and from 0.00 wt % to 0.50 wt % of a biuret impurity of formula (A) relative to the total weight of ensifentrine. Further disclosed herein are liquid pharmaceutical compositions comprising the particulate composition, and a process for producing the particulate composition are also described.

The invention belongs to the technical field of bionic nano-drugs, and particularly relates to a bionic vesicle preparation as well as a preparation method and application thereof. The bionic vesicle preparation disclosed by the invention is prepared from the following raw materials: mesenchymal stem cell outer vesicles, nintedanib and DSPE-PEG-HA (hyaluronic acid modified pegylated phospholipid); the nintedanib is loaded in the mesenchymal stem cell outer vesicle, and the DSPE-PEG-HA is coupled to the surface of the mesenchymal stem cell outer vesicle. The bionic vesicle preparation disclosed by the invention can be used for directly delivering a drug to a pulmonary fibrosis injury part through inhalation type drug delivery, and acting on a focus part at a higher local concentration, meanwhile, the exposure of the drug in whole-body circulation is remarkably reduced, the occurrence of side effects is reduced, and the specific targeting intervention and regulation on fibroblasts are realized.

Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for primary ciliary dyskinesia (PCD), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject.

Compounds of formula (I)wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

There are disclosed deuterated 2C—X phenethylamine compounds. the use of such compounds in the treatment of diseases associated with a serotonin 5-HIT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds. methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.

The invention relates to a nano preparation for delivering antibiotics based on plant extracts and application of the nano preparation, and belongs to the technical field of nano preparations. In order to solve the problems of low bioavailability and low action efficiency of oral administration or intravenous injection of antibiotics in the lung disease treatment process, the invention provides a nano preparation for delivering antibiotics based on plant extracts. The mass volume ratio of the antibiotics to the plant extract in the nano preparation is (1-10) mg: (20-100) mu L. The nano preparation disclosed by the invention can obviously inhibit the migration of fibroblasts, has an obvious bacteriostatic effect and can reduce the density of microorganisms in lungs; positive charges carried by the material are combined with negative charges on the surface of a bacterial cell membrane, transmembrane substance transfer on the bacterial cell membrane is affected, bacterial metabolism and reproduction are affected, adjustment of pulmonary symbiotic bacteria is better achieved, and the pulmonary fibrosis progress can be relieved. The nano preparation has the advantages of small toxic and side effects, good patient compliance, high encapsulation efficiency and the like.

Improved systems, compositions, and methods of treating infections with antimicrobials are provided, having reduced risk of creating or promoting drug- resistant microbes or superinfections, where one or more antimicrobials susceptible to drug-resistant organisms are applied via an aerosol delivery device in combination with an EDTA solution at elevated pH.

Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for primary ciliary dyskinesia (PCD), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject.

The invention relates to a polymyxin inhalation liquid preparation and a preparation method thereof. The polymyxin inhalation liquid preparation comprises 0.1-5% (W / V) of polymyxin B sulfate, 0.05-1% (W / V) of a stabilizer, 0.1-0.9% (W / V) of an osmotic pressure regulator, a pH value regulator and a solvent, the pH (Potential of Hydrogen) of the liquid preparation is 3.0 to 6.0; the solvent is selected from purified water and water for injection; the polymyxin inhalation solution provided by the invention is simple in composition, the pH value of the polymyxin inhalation solution is 3.0-6.0, osmotic pressure and isotonic pressure are simultaneously realized, bronchus spasm and cough caused by the polymyxin inhalation solution can be reduced, safety evaluation verifies that the polymyxin inhalation solution has better safety, and a new choice is provided for clinical application.

There are disclosed phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the disclosed compounds.

The disclosure relates to a particulate composition comprising ensifentrine, wherein the particulate composition further comprises: from greater than 0.00 wt % to 0.60 wt % of 1,3-bis(2-(2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6, 1-a]isoquinolin-3(4H)-yl)ethyl)urea (BMIQU) relative to the total weight of ensifentrine; and from 0.00 wt % to 0.50 wt % of a biuret impurity of formula (A) relative to the total weight of ensifentrine. Further disclosed herein are liquid pharmaceutical compositions comprising the particulate composition, and a process 10 for producing the particulate composition are also described.

The present invention relates to a process for producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentrine particles, wherein the process comprises: (a) heating ensifentrine particles at a temperature of from 100° C. to 220° C. to obtain sterile ensifentrine particles; and (b) combining the sterile ensifentrine particles with a sterile liquid vehicle to produce the sterile liquid pharmaceutical composition suitable for administration by inhalation. A process for producing an ampule comprising the sterile liquid pharmaceutical composition is also described.

The present invention relates i.a. to an IBV (infectious bronchitis virus) encoding for a heterologous DMV S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said IBV encoding for a heterologous DMV S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

The invention relates to the technical field of biological medicine, in particular to a composite drug-loaded nano preparation and a preparation method thereof. The composite drug-loaded nano-preparation comprises a drug-loaded nano-liposome, and a biological enzyme and a myofibroblast targeting ligand which are loaded on the surface of the drug-loaded nano-liposome, the drug-loaded nano-liposome is a nano-liposome in which an anti-fibrosis drug is encapsulated; the mass ratio of the drug-loaded nano-liposome to the biological enzyme to the myofibroblast targeting ligand is (6-15): (0.5-4): (0-3). According to the invention, a composite drug-loaded nano preparation for pulmonary drug delivery in an aerosol inhalation manner is constructed, and the myofibroblast targeting ligand and the biological enzyme are jointly modified on the surface of the drug-loaded nano liposome; and the composite nano preparation (CLG-CS-FAP-NIN) which has myofibroblast targeting and can degrade excessive collagen in an extracellular matrix is prepared and is used for treating the pulmonary fibrosis.

The invention includes methods of preventing or treating acute lung injury using a MAP3K2 / MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention.

Disclosed herein include methods, compositions, and kits suitable for use in preventing or relieving side effects associated with the administration of a weight loss medication. The method can comprise administering to a subject under a weight loss treatment a composition comprising a neurokinin 1 receptor (NK1R) antagonist (e.g., aprepitant).

Disclosed herein are kits and methods for treating pulmonary arterial hypertension (PAH), the method comprising administering to a subject in need thereof: * a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically acceptable salt thereof; and * a therapeutically effective amount of a dimeric fusion protein comprising: * an extracellular domain of activin type 2A (ACTR IIA) or activin type 2B receptor (ACTR IIB); and an Fc domain of human immunoglobulin G1 (IgG1). In some embodiments, the tyrosine kinase inhibitor is cellatinib or a pharmaceutically acceptable salt thereof, and the fusion protein is sotasercept.

Improved systems, compositions, and methods of treating infections with antimicrobials are provided, having reduced risk of creating or promoting drug-resistant microbes or superinfections, where one or more antimicrobials susceptible to drug-resistant organisms are applied via an aerosol delivery device in combination with an EDTA solution at elevated pH.

Provided herein are compositions comprising caveolin-1 (Cav-1) peptides. Further provided are methods of using the Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

Provided are compositions containing extracellular vesicles from microalgae (MEVs) that are loaded with bioactive cargo. The MEVs are formulated and administered by a variety of routes of administration and have a variety of applications as therapeutics, including as vaccines, as anti-cancer therapeutics, as therapeutics for psychiatric diseases, disorders, and conditions, and as diagnostics, and other such uses.

Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.

The invention discloses a refenasin triphenyl acetate and an inhalation powder inhalation thereof. The refenasin triphenyl acetate can be prepared into inhalation powder inhalation, has the effects of good preparation stability, high deposition proportion in an effective part in a body, good curative effect and low side effect, and provides a new drug choice for treatment of COPD patients.

The inhalation suspension preparation containing the SGC receptor stimulant comprises the SGC receptor stimulant with an effective therapeutic dose or pharmaceutically acceptable salt of the SGC receptor stimulant, and pharmaceutically acceptable auxiliary materials of the suspension preparation, the pharmaceutically acceptable auxiliary materials of the suspension preparation comprise at least one of a surfactant, a pH regulator, an osmotic pressure regulator and a metal complexing agent; the inhalation suspension preparation containing the riociguat shows good lung absorption efficiency, is beneficial to reaching the same or better treatment level by reducing the administration dosage, can directly act on a diseased region through an administration route, takes effect more quickly compared with oral administration of the riociguat, and has a good application prospect. Gastrointestinal discomfort and systemic hypotension side effects caused by gastrointestinal tract contact and absorption entering a circulatory system can be avoided, the treatment cycle of an oral dosage form dosage titration administration scheme is shortened, and a better treatment scheme is provided for relieving dyspnea and syncope symptoms of pulmonary hypertension patients treated at home.